Biologics Safety Testing Market 10-Year Market Forecast and Trends Analysis Research Report 2019-2029 – Jewish Life News

Changing landscape of healthcare markets around the world have propelled the need for having a deep understanding before measuring the future of pharmaceutical manufacturing procedures such as biologics safety testing. Designing these genetically-engineered proteins called biologics, which are derived from human genes, involves a series of testing procedures to weigh their safety in treatment of various disorders, and their inclusion in production of drugs and medicine. XploreMR has developed a market study, titled Biologics Safety Testing Market: Global Industry Analysis (2012-2016), and Forecast (2017-2022), which offers insights on the foreseeable future of global market for biologics safety testing. The report has analyzed key trends influencing the dynamics ofbiologics safety testing market, delivering global market size valuations over a five-year historical period. These assessments have been redirected as primary reference to construe estimations on the global biologics safety testing market for the forecast period, 2017-2022.

Report Synopsis

The first section in the report offers an executive summary, wherein the analyzed and anticipated expansion of global biologics safety testing market across various regions has been highlighted. The report offers a comprehensive overview of the market, which includes a formal introduction to the global biologics safety testing market, and a standard definition on biologics safety testing. This section offers market size estimations in metrics such as compounded annual growth rates (CAGRs) and Year-on-Year (Y-o-Y) growth rates.

The report further delivers an analysis on industry trends, cost structure, pricing, and supply chain. Factors impacting the growth of biologics safety testing market have also been analyzed, and the report also delivers an illustrative intensity map that plots the presence of market participants across all regions.

Key chapters in the report offer a segmented analysis and forecast on the global biologics safety testing market. The global market for biologics safety testing has been segmented on the basis of product-type, test-type, application, and region. These sections also provide cross-segmental data and country-wise market analysis & forecast. The report concludes by profiling key market players in detail. This section reveals the overall competitive landscape of the global biologics safety testing market, tracking all notable developments of companies and disclosing their current market standings.

Market Taxonomy

A concise taxonomy on the global market for biologics safety testing has been summarized in the table below:

Region

Product Type

Test Type

This Press Release will help you to understand the Volume, growth with Impacting Trends. Click HERE To get SAMPLE PDF (Including Full TOC, Table & Figures) athttps://www.xploremr.com/connectus/sample/4911

Application

North America

Kits & Reagents

Endotoxin Tests

Vaccine and Therapeutics Development

Latin America

Instruments

Sterility Tests

Blood and Blood-related Products Testing

Europe

Services

Request Report Methodology at https://www.xploremr.com/connectus/request-methodology/4911

Cell Line Authentication and Characterization Tests

Cellular and Gene Therapy

Japan

Residual Host Contamination Detection Tests

Tissue and Tissue-related Products Testing

APEJ

Adventitious Agent Detection Tests

Stem Cell Research

MEA

Bioburden Tests

Other Tests

Research Methodology

Our research methodology is underpinned by robust methodical approaches adopted by our analysts. Firstly, data on revenues of market participants is procured by secondary and primary resources, which include authoritative databases. This data is aggregated to generate market size estimations for the past five years. Quantitative data is further infused with qualitative insights to offer an assorted assessment on the future of biologics safety testing. Market size estimations have been quantified in US dollars (US$) by converting regional market evaluations with 2017 currency exchange rates. The report has also enlisted key mergers & acquisitions encompassing the global biologics safety testing market, underlining the strategic undertakings of market players towards product development and long-term remunerative gains. The scope of the report is to enable companies boost their presence in the overall biologics safety testing market by taking informed decisions. Research findings and market forecasts availed in this report can be used as guidelines for developing strategic goals in future market direction.

Buy Full Report at https://www.xploremr.com/cart/4911/SL

About Us

XploreMR, a leading market research firm, headquartered in San Jose, USA, XploreMR has, in a short span of time, served the market research needs of some of the biggest Fortune 500 companies. XploreMR also has highly personalized market research offerings for SMEs, and we pride ourselves on being uniquely positioned to have worked with colossal multinational firms and small, boutique firms. Our experience of working with such a diverse set from all over the world has given us invaluable perspectives on objectives, outlooks, goals, and eventually, the collective, symbiotic growth that stakeholders across the value chain aspire for. We keep these perspectives and aspirations in mind every time we work on a project, and this motivates us to exceed client expectations on a consistent basis.

Contact us: XploreMR 111 North Market Street, Suite 300, San Jose, CA 95113, United States Ph.No: +16692840108 E-mail id- [emailprotected] Web- https://www.xploremr.com

See the original post here:
Biologics Safety Testing Market 10-Year Market Forecast and Trends Analysis Research Report 2019-2029 - Jewish Life News

Stem Cell Therapy for Osteoarthritis Market: Global Growth Manufacturers, Regions, Product Types, Major Application Analysis & Forecast to 2026 -…

The Global Stem Cell Therapy for Osteoarthritis market report offers key information about the industry, helpful and important facts and figures, expert opinions, and the latest developments across the world. The research report represents a comprehensive presumption of the market and encloses imperative future estimations, industry-authenticated figures, and facts of the global market. It predicts inclinations and augmentation statistics with emphasis on abilities & technologies, markets & industries along with the variable market trends. The Stem Cell Therapy for Osteoarthritis market report analyses and notifies the industry statistics at the global as well as regional and country levels to acquire a thorough perspective of the entire Stem Cell Therapy for Osteoarthritis market.

The Stem Cell Therapy for Osteoarthritis market report intends to offer significant information of this business space while elaborating on the key global trends. The document emphasizes on the growth opportunities as well as the drivers that will influence the profitability graph of this business vertical over the estimated timeframe. It also measures the challenges & restraints that may inhibit the expansion of the market.

Request Sample Copy of this Report @ https://www.cuereport.com/request-sample/25044

The research repot delivers a comparative statement regarding the existing and predicted market scenario to derive the growth rate of this industry vertical over the study duration. Additionally, it measures the effect of COVID-19 outbreak on the regional as well as overall market to denote the methodologies that can help in decision making.

Request Sample Copy of this Report @ https://www.cuereport.com/request-sample/25044

Major details from Table of Contents:

Product landscape

Application scope

Regional Analysis

Competitive arena

In short, the Stem Cell Therapy for Osteoarthritis market provides a granular assessment through numerous segmentations, while evaluating the other aspects including sales channel and supply chain processes which consist of downstream buyers, upstream suppliers, and distributors of this business space.

Key Answers Captured in Study Objectives are

Request Customization on This Report @ https://www.cuereport.com/request-for-customization/25044

Go here to see the original:
Stem Cell Therapy for Osteoarthritis Market: Global Growth Manufacturers, Regions, Product Types, Major Application Analysis & Forecast to 2026 -...

Hunter Syndrome Treatment Market 2020 Recent Industry Developments and Growth Strategies Adopted by Top Key Players Worldwide and Assessment to 2024 -…

The newly added market research report by Report Ocean on Hunter Syndrome Treatment Market helps in understanding Hunter Syndrome Treatment Market dynamics, structure by identifying and analyzing the market segments and project the global market size. Further, the report also focuses on the competitive analysis of key players by product, price, financial position, product portfolio, growth strategies, and regional presence.

The objective of the report is to present a comprehensive assessment of the market and contains thoughtful insights, facts, historical data, industry-validated market data and projections with a suitable set of assumptions and methodology. The report also provides PEST analysis, PORTERs analysis, SWOT analysis to address questions of shareholders to prioritizing the efforts and investment in the near future to the emerging segment in the Hunter Syndrome Treatment Market.

COVID- 19 Impact on Hunter Syndrome Treatment Market

As companies move from reacting to mitigating the impact of the COVID-19 outbreak, they are keenly focusing on strategies that may result in emerging as strong market player. This market research report included the detailed study related to impact of COVID-19 on the supply chain based on both downstream and upstream markets. The report also includes the future development in the Hunter Syndrome Treatment Market in relation with the impact of COVID-19 on the market.

Request Free Sample Report athttps://www.reportocean.com/industry-verticals/sample-request?report_id=bis62183

Competitive Landscape:

This section of the report has mainly focused on Key Strategies adopted by leading players in Hunter Syndrome Treatment Market. These companies are selected based on revenue, innovations, strength of product portfolio, regional presence, investment capacity and similar other factors.

Takeda GC Pharma. JCR Pharmaceuticals Co Ltd. RegenxBio Inc. Sangamo Therapeutics, Inc. ArmaGen Inc. Inventiva S.A. Denali Therapeutics Inc. Bioasis Technologies Inc. Esteve

Market Segmentation:

The segmentation is used to decide the target market into smaller sections or segments like product type, application, and geographical regions to optimize marketing strategies, advertising technique and global as well as regional sales efforts of Hunter Syndrome Treatment Market.

Product Type Segmentation Enzyme Replacement Therapy (ERT) Hematopoietic Stem Cell Transplant (HSCT)

Industry Segmentation Life Science Companies Research Institutes Hospital

Channel (Direct Sales, Distributor) Segmentation

Region Segmentation:

Each region is exhaustively researched about so that players can use the analysis to tap into unexplored markets and plan powerful strategies to gain a foothold in Hunter Syndrome Treatment Market. The regional analysis section of the report offers an extensive analysis of the Hunter Syndrome Treatment Market based on region. The Hunter Syndrome Treatment Market will showcase a steady CAGR in the forecast year.

North America Country (United States, Canada)

South America

Asia Country (China, Japan, India, Korea)

Europe Country (Germany, UK, France, Italy)

Other Country (Middle East, Africa, GCC)

Table of Contents of Hunter Syndrome Treatment Market

Report Overview: This section of report includes major players of the Hunter Syndrome Treatment Market covered in the research study, research scope, and Market segments by type, market segments by application, years considered for the research study, and objectives of the report.

Global Growth Trends: This section focuses on industry trends where market drivers and top market trends are shed light upon. It also provides growth rates of key producers operating in the Hunter Syndrome Treatment Market Furthermore, it offers production and capacity analysis where marketing pricing trends, capacity, production, and production value of the Hunter Syndrome Treatment Market are discussed.

Market Share by Manufacturers: Here, the report provides details about revenue by manufacturers, production and capacity by manufacturers, price by manufacturers, expansion plans, mergers and acquisitions, and products, market entry dates, distribution, and market areas of key manufacturers.

Market Size by Type: This section concentrates on product type segments where production value market share, price, and production market share by product type are discussed.

Market Size by Application: Besides an overview of the Hunter Syndrome Treatment Market by application, it gives a study on the consumption in the Hunter Syndrome Treatment Market by application.

Production by Region: Here, the production value growth rate, production growth rate, import and export, and key players of each regional market are provided.

Consumption by Region: This section provides information on the consumption in each regional market studied in the report. The consumption is discussed based on country, application, and product type.

Company Profiles: Almost all leading players of the Hunter Syndrome Treatment Market are profiled in this section. The analysts have provided information about their recent developments in the Hunter Syndrome Treatment Market, products, revenue, production, business, and company.

Market Forecast by Production: The production and production value forecasts included in this section are for the Hunter Syndrome Treatment Market as well as for key regional markets.

Market Forecast by Consumption: The consumption and consumption value forecasts included in this section are for the Hunter Syndrome Treatment Market as well as for key regional markets.

Value Chain and Sales Analysis: It deeply analyzes customers, distributors, sales channels, and value chain of the Hunter Syndrome Treatment Market.

Key Findings: This section gives a quick look at important findings of the research study.

For more information and discount on this report, ask your query at:https://www.reportocean.com/industry-verticals/sample-request?report_id=bis62183

Thanks for reading this article; you can also get individual chapter wise section or region wise report version like North America, Europe, and Asia.

Contact Us: +1 888 212 3539 (US) +91-9997112116 (Outside US) Contact Person: Tom Email:[emailprotected]

Read the original post:
Hunter Syndrome Treatment Market 2020 Recent Industry Developments and Growth Strategies Adopted by Top Key Players Worldwide and Assessment to 2024 -...

Study finds the real reason you get goosebumps – Big Think

Everybody gets goosebumps, but have you ever wondered why? Until now, the leading hypothesis was that by elevating hair-follicles on the skin, goosebumps helped keep the body warm by providing more space for warm air to be collect near the body. However, many scientists have puzzled over this explanation, as the lack of body hair on modern humans leaves us with the ability to have goose skin but without the ability to benefit from it.

Evolutionarily, that makes little sense, if it really was that useless we'd expect more than a few people to not have the ability to get them by now.

A new study published in Cell suggests a different reason for this reaction. Its authors argue that the same cells that cause goosebumps might be responsible for helping hair growth in the first place, giving a reason for evolution to retain this familiar phenomenon.

In animals, many organs are made of three kinds of tissue: epithelium, mesenchyme, and nerve. In the skin, which is an organ, a nerve connects to muscle in the mesenchyme. This nerve is part of the sympathetic nervous system and helps maintain homeostasis. The muscle itself is connected to stem cells in the epithelium that heal wounds and regenerate hair follicles.

The researchers focused on mice, as is typical in these studies, but suggest that the findings are also applicable to humans given the similarity between our skin and hair cells.

The researchers examined the behavior and structure of the nerve under an electron microscope. To their surprise, the nerve was not only attached to the previously mentioned muscle tissue but also wrapped around hair follicle stem cells.

In normal conditions, the sympathetic nervous system is always operating at a low level. This keeps the body functioning normally. When the researchers observed this behavior, they noticed signals being sent by the nervous system to the stem cells in the hair follicles. These signals seem to keep the stem cells at the ready for potential use.

However, when the researchers exposed the tissues to the cold, the activity ramped up. A flood of neurotransmitters was released, and the stem cells activated. This prompted new hair growth to begin.

Another experiment dove into how the nerve reached the stem cells in the first place. Co-Author Yulia Shwartz explained the findings in a press release:

"We discovered that the signal comes from the developing hair follicle itself. It secretes a protein that regulates the formation of the smooth muscle, which then attracts the sympathetic nerve. Then in the adult, the interaction turns around, with the nerve and muscle together regulating the hair follicle stem cells to regenerate the new hair follicle. It's closing the whole circle -- the developing hair follicle is establishing its own niche."

Putting this together, it appears that goosebumps are part of a two-phased response to cold. In the first, the muscle below the skin is stimulated to form goosebumps. If this stimulation lasts long enough, the second phase kicks in, with the sympathetic nervous system calling for new hair growth and repairs for the old ones to be made in response to the cold.

In their press release, the authors suggest that further research can focus on how the body repairs itself in response to environmental stimuli in various situations. The findings also imply that other currently unsuspected connections between the sympathetic nervous system and other parts of the body exist. These potential interactions will undoubtedly be searched for and examined.

Everybody gets goosebumps now and then. We've always assumed we knew why we still get them, even though the hypothesis had some holes. This study's findings show that the benefits of getting goosebumps are more complex than initially thought. It just goes to remind us that we still have much to learn about even the most mundane things.

Related Articles Around the Web

Follow this link:
Study finds the real reason you get goosebumps - Big Think

The Global Apoptosis Assays Market is expected to grow from USD 3,753.69 Million in 2019 to USD 6,153.93 Million by the end of 2025 at a Compound…

Market Segmentation & Coverage: This research report categorizes the Apoptosis Assays to forecast the revenues and analyze the trends in each of the following sub-markets:

New York, July 24, 2020 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Apoptosis Assays Market Research Report by Product, by Detection Technology, by Application, by End User - Global Forecast to 2025 - Cumulative Impact of COVID-19" - https://www.reportlinker.com/p05913231/?utm_source=GNW On the basis of Product, the Apoptosis Assays Market is studied across Assay Kits, Instruments, Microplates, and Reagents. The Assay Kits further studied across Annexin V and Cell Permeability Assays, Caspase assays, DNA Fragmentation Assays, and Mitochondrial Assays.

On the basis of Detection Technology, the Apoptosis Assays Market is studied across Cell Imaging and Microscopy, Flow Cytometry, and Spectrophotometry.

On the basis of Application , the Apoptosis Assays Market is studied across Basic Research, Clinical and Diagnostic Applications, Drug Discovery and Development, and Stem Cell Research.

On the basis of End User, the Apoptosis Assays Market is studied across Academic & Research Institutes, Hospital & Diagnostic Laboratories, and Pharmaceutical & Biotechnology Companies.

On the basis of Geography, the Apoptosis Assays Market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas region is studied across Argentina, Brazil, Canada, Mexico, and United States. The Asia-Pacific region is studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, South Korea, and Thailand. The Europe, Middle East & Africa region is studied across France, Germany, Italy, Netherlands, Qatar, Russia, Saudi Arabia, South Africa, Spain, United Arab Emirates, and United Kingdom.

Company Usability Profiles: The report deeply explores the recent significant developments by the leading vendors and innovation profiles in the Global Apoptosis Assays Market including Abcam PLC, Becton, Dickinson and Company, Bio-Rad Laboratories, Bio-Techne Corporation, Biotium, Creative Bioarray (A Part of Creative Dynamics Inc.), Danaher Corporation, GE Healthcare, GeneCopoeia, Inc., Geno Technology, Inc., Merck KGaA, Promega Corporation, Sartorius AG, and Thermo Fisher Scientific Inc..

FPNV Positioning Matrix: The FPNV Positioning Matrix evaluates and categorizes the vendors in the Apoptosis Assays Market on the basis of Business Strategy (Business Growth, Industry Coverage, Financial Viability, and Channel Support) and Product Satisfaction (Value for Money, Ease of Use, Product Features, and Customer Support) that aids businesses in better decision making and understanding the competitive landscape.

Competitive Strategic Window: The Competitive Strategic Window analyses the competitive landscape in terms of markets, applications, and geographies. The Competitive Strategic Window helps the vendor define an alignment or fit between their capabilities and opportunities for future growth prospects. During a forecast period, it defines the optimal or favorable fit for the vendors to adopt successive merger and acquisition strategies, geography expansion, research & development, and new product introduction strategies to execute further business expansion and growth.

Cumulative Impact of COVID-19: COVID-19 is an incomparable global public health emergency that has affected almost every industry, so for and, the long-term effects projected to impact the industry growth during the forecast period. Our ongoing research amplifies our research framework to ensure the inclusion of underlaying COVID-19 issues and potential paths forward. The report is delivering insights on COVID-19 considering the changes in consumer behavior and demand, purchasing patterns, re-routing of the supply chain, dynamics of current market forces, and the significant interventions of governments. The updated study provides insights, analysis, estimations, and forecast, considering the COVID-19 impact on the market.

The report provides insights on the following pointers: 1. Market Penetration: Provides comprehensive information on sulfuric acid offered by the key players 2. Market Development: Provides in-depth information about lucrative emerging markets and analyzes the markets 3. Market Diversification: Provides detailed information about new product launches, untapped geographies, recent developments, and investments 4. Competitive Assessment & Intelligence: Provides an exhaustive assessment of market shares, strategies, products, and manufacturing capabilities of the leading players 5. Product Development & Innovation: Provides intelligent insights on future technologies, R&D activities, and new product developments

The report answers questions such as: 1. What is the market size and forecast of the Global Apoptosis Assays Market? 2. What are the inhibiting factors and impact of COVID-19 shaping the Global Apoptosis Assays Market during the forecast period? 3. Which are the products/segments/applications/areas to invest in over the forecast period in the Global Apoptosis Assays Market? 4. What is the competitive strategic window for opportunities in the Global Apoptosis Assays Market? 5. What are the technology trends and regulatory frameworks in the Global Apoptosis Assays Market? 6. What are the modes and strategic moves considered suitable for entering the Global Apoptosis Assays Market? Read the full report: https://www.reportlinker.com/p05913231/?utm_source=GNW

About Reportlinker ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.

__________________________

More here:
The Global Apoptosis Assays Market is expected to grow from USD 3,753.69 Million in 2019 to USD 6,153.93 Million by the end of 2025 at a Compound...

Stem Cell Therapy Market Research Report 2020 Segment by Key Companies, Countries, Types, Applications and Forecast to 2025 – 3rd Watch News

Global Stem Cell Therapy Market 2020-2025 is one of the most comprehensive and important additions to Adroit Market Research archive of market research studies. It offers detailed research and analysis of key aspects of the global market. The market analysts authoring this report have provided in-depth information on leading growth drivers, restraints, challenges, trends, and opportunities to offer a complete analysis of the global Stem Cell Therapy market. The report also analyzes factors such as drivers, restraints, opportunities, and trends affecting the market growth. It evaluates the opportunities and challenges in the market for stakeholders and provides particulars of the competitive landscape for market leaders.

Get sample copy of Stem Cell Therapy Market report @https://www.adroitmarketresearch.com/contacts/request-sample/691

The analysis is likely to create in-depth analysis predicated on preceding questions and comprehensive research regarding the evolution setting, market dimensions, development tendency, performance status and future development tendency of Stem Cell Therapy market on based on saying current position 2020 therefore as to create complete organization and decision on your contest situation and development tendency of global Stem Cell Therapy market and assist brands and investment company to grasp the growth span of the market.

Read complete report with TOC at:https://www.adroitmarketresearch.com/industry-reports/stem-cell-therapy-market

Stem Cell Therapy market is split by Type and by Application. For the period 2020-2025, the growth among segments provide accurate calculations and forecasts for sales by Type and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets. Stem Cell Therapy market competitive landscape provides details by vendors, including company overview, company total revenue, market potential, global presence, sales and revenue generated, market share, price, production sites and facilities, SWOT analysis.

Global Stem Cell Therapy market is segmented based by type, application and region.

Based on Type, the market has been segmented into:

Based on cell source, the market has been segmented into,

Adipose Tissue-Derived Mesenchymal SCs Bone Marrow-Derived Mesenchymal SCs Embryonic SCs Other Sources

Based on application, the market has been segmented into:

Based on therapeutic application, the market has been segmented into,

Musculoskeletal Disorders Wounds & Injuries Cardiovascular Diseases Gastrointestinal Diseases Immune System Diseases Other Applications

Stem Cell Therapy market study further highlights the segmentation of the Stem Cell Therapy industry on a global distribution. The report focuses on regions of North America, Europe, Asia, and the Rest of the World in terms of developing business trends, preferred market channels, investment feasibility, long term investments, and environmental analysis. The Stem Cell Therapy market report also calls attention to investigate product capacity, product price, profit streams, supply to demand ratio, production and market growth rate, and a projected growth forecast.

In addition, the Stem Cell Therapy market study also covers several factors such as market status, key market trends, growth forecast, and growth opportunities. Furthermore, we analyze the challenges faced by the Stem Cell Therapy market in terms of global and regional basis. The study also encompasses a number of opportunities and emerging trends which are considered by considering their impact on the global scale in acquiring a majority of the market share.

Do You Have Any Query Or Specific Requirement? Ask to Our Industry Expert @https://www.adroitmarketresearch.com/contacts/enquiry-before-buying/691

About Us :

Adroit Market Research is an India-based business analytics and consulting company. Our target audience is a wide range of corporations, manufacturing companies, product/technology development institutions and industry associations that require understanding of a markets size, key trends, participants and future outlook of an industry. We intend to become our clients knowledge partner and provide them with valuable market insights to help create opportunities that increase their revenues. We follow a code Explore, Learn and Transform. At our core, we are curious people who love to identify and understand industry patterns, create an insightful study around our findings and churn out money-making roadmaps.

Contact Us :

Ryan Johnson Account Manager Global 3131 McKinney Ave Ste 600, Dallas, TX 75204, U.S.A Phone No.: USA: +1 972-362 -8199 / +91 9665341414

Go here to read the rest:
Stem Cell Therapy Market Research Report 2020 Segment by Key Companies, Countries, Types, Applications and Forecast to 2025 - 3rd Watch News

Two Immunotherapies Converted Into Single Therapy for Certain Blood Cancers – Technology Networks

Researchers at Washington University School of Medicine in St. Louis have combined two types of immunotherapy into a single treatment that may be more effective and possibly safer than current immunotherapies for blood cancers. Shown is a type of immune cell called a memory-like natural killer cell (right) attacking a leukemia cell (left). In the new study, the researchers modified the natural killer cells to help them find the leukemia cells more effectively. Credit: Julia Wagner

Read Time:

Some of the most promising advances in cancer treatment have centered on immunotherapies that rev up a patients immune system to attack cancer. But immunotherapies dont work in all patients, and researchers have been searching for ways to increase their effectiveness.

Now, researchers at Washington University School of Medicine in St. Louis have combined two immunotherapy strategies into a single therapy and found, in studies in human cells and in mice, that the two together are more effective than either alone in treating certain blood cancers, such as leukemia. Evidence also suggests that the new approach could be safer than one of the most recent cellular immunotherapies to be approved by the FDA, called CAR-T cell therapy, in which the immune systems T cells are engineered to target tumor cells. Cell-based immunotherapies are most commonly used against blood cancers but can be harnessed against some solid tumors as well, such as prostate and lung tumors and melanoma.

The study appears online in the journal Blood.

In the new research, the scientists have harnessed the technology used to engineer CAR-T cells and, instead of modifying specialized immune cells called T cells, they have used similar technology to alter different immune cells called natural killer (NK) cells. The resulting immunotherapy combines the benefits of both strategies and may reduce the side effects that are sometimes seen in CAR-T cell therapy. In some patients, for example, CAR-T cell therapy causes a cytokine storm, a life-threatening overreaction of the immune system.

Immunotherapies show great promise for cancer therapy, but we need to make them more effective and more safe for more patients, said co-senior authorTodd A. Fehniger, MD, PhD, a professor of medicine. This combined approach builds on the treatment strategy that we developed for leukemia patients using natural killer cells. We can supercharge natural killer cells to enhance their ability to attack cancer cells. And at the same time, we can use the genetic engineering approaches of CAR cell therapy to direct the natural killer cells to a tumor target that would normally be overlooked by NK cells. It fundamentally changes the types of cancer that NK cells could be used to treat, both additional blood cancers and potentially solid tumors as well.

In past work, Fehniger and his colleagues showed that they could collect a patients own NK cells, expose the cells to a specific recipe of chemical signals that prime the cells to attack tumors, and then return the primed cells to patients for therapy. This chemical exposure is a sort of basic training for the cells, according to the investigators, preparing the NK cells to fight the cancer. When the cells are then returned to the body, they remember their training, so to speak, and are more effective at targeting the tumor cells. Because their training has given the NK cells a memory of what to do when they encounter tumor cells, the researchers dubbed them memory-like NK cells.

In small clinical trials conducted atSiteman Cancer Centerat Barnes-Jewish Hospital and Washington University School of Medicine, such cells were effective in putting some patients with leukemia into a lasting remission, but they didnt work for everyone. Some tumor cells still evaded the memory-like NK cells, despite the cells basic training. To help the cells find the tumor cells, so their basic training can kick in and kill the correct target, the researchers modified the memory-like NK cells with the same CAR (chimeric antigen receptor) molecule that is typically used to target T cells to tumor cells. The CAR molecule is flexible and can be modified to direct the cells to different tumor types, depending on the proteins on the surfaces of the cancer cells.

The resulting hybrid cells were more effective in treating mice with leukemia than memory-like NK cells alone, leading to longer survival for mice treated with CAR memory-like NK cells. The researchers also found the therapy to be effective despite the fact that the mice were given relatively low doses of the cells.

One aspect of this study I find most exciting is how nicely these hybrid NK cells expand in the mice to respond to their tumors, said co-senior authorMelissa Berrien-Elliott, PhD, an instructor in medicine. We can provide a tiny dose and see an incredible amount of tumor control. To me, this highlights the potency of these cells, as well as their potential to expand once in the body, which is critical for translating these findings to the clinic.

Fehniger also pointed out that an advantage of NK cells in general and for biological reasons that the scientists are still working to understand NK cells dont trigger a dangerous immune response or the long-term side effects that T-cell therapy can cause in attacking the patients healthy tissues, a condition called graft-versus-host disease.

In all of the clinical trials exploring any type of NK cells, we dont see the troublesome side effects of cytokine release syndrome or neurotoxicity that we see with CAR-T cells that can profoundly affect patients, Fehniger said. These side effects can be life-threatening and require intensive care. Were still working to understand how NK cells are different. But if you can get the benefits of CAR-T cells with few if any of the side effects, thats a reasonable line of research to pursue. Another benefit of this safer therapy is the potential to give these cells to patients at an earlier stage in their disease, rather than using them as a last resort.

Other groups have developed CAR-NK cells, but a major difference is that other groups NK cells came from donated cord blood or induced stem cells, rather than adult donors or the patients themselves.

The other groups have artificially differentiated stem cells into something that resembles an NK cell, Fehniger said. With that strategy, theres no guarantee that those cells will have all the properties of typical mature NK cells. In contrast, were starting with adult NK cells, so were more confident that they will have all the inherent properties and behavior of adult NK cells, which we have already shown to be effective in certain types of cancer patients, especially those with leukemia. Inducing memory properties adds to their persistence and effectiveness against many cancer types.

Over the next several years, we would like to be able to scale up this process to produce enough cells for a first-in-human clinical trial, and investigate their effectiveness in different types of human blood cancers, he said.

Reference: Gang, et al. (2020). CAR-modified memory-like NK cells exhibit potent responses to NK-resistant lymphomas. Blood. DOI: https://doi.org/10.1182/blood.2020006619

This article has been republished from the following materials. Note: material may have been edited for length and content. For further information, please contact the cited source.

View original post here:
Two Immunotherapies Converted Into Single Therapy for Certain Blood Cancers - Technology Networks

Stem Cell Therapy Market to Surpass US$ 40.3 Billion by 2027, Owing to Increasing Incidence of Spina – PharmiWeb.com

The complete version of the Report will include the impact of the COVID-19, and anticipated change on the future outlook of the industry, by taking into the account the political, economic, social, and technological parameters.

According to Global Stem Cell Therapy Market Report, by Cell Source (Adult Stem Cells, Induced Pluripotent Stem Cells, Embryonic Stem Cells, and Others), by Application (Musculoskeletal Disorders, Wounds and Injuries, Cancer, Autoimmune Disorders, and Others), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa), published by Coherent Market Insights, the global stem cell therapy market was valued at US$ 7,313.6 million in 2018, and is expected to exhibit a CAGR of 21.1% over the forecast period (2019-2027).

Increasing incidence of spinal cord injuries is expected to boost growth of the global stem cell therapy market over the forecast period. For instance, according to the National Spinal Cord Injury Statistical Center, 2016, the annual incidence of spinal cord injury (SCI) was approximately 54 cases per million population in the U.S. or approximately 17,000 new SCI cases each year. Moreover, high prevalence of leukemia is also expected to aid in growth of the market. For instance, according to the Leukemia and Lymphoma Society, 2017, around 172,910 people in the U.S. were diagnosed with leukemia, lymphoma or myeloma in 2017.

*The Download PDF brochure only consist of Table of Content, Research Framework, and Research Methodology.

Request PDF Research Report Brochure @ https://www.coherentmarketinsights.com/insight/request-pdf/2848

R&D of induced pluripotent stem cells is expected to boost growth of the global stem cell therapy market over the forecast period. For instance, in April 2019, Fate Therapeutics collaborated with UC San Diego to launch off-the-shelf immunotherapy (FT500), which was developed from human induced pluripotent stem cells.

Among regions, North America accounted for the largest share in the global stem cell therapy market in 2018, and is expected to retain its dominance over the forecast period. This is attributed to increasing number of clinical trials related to stem cell therapy. For instance, in April, 2019, UCLA-UCI Alpha Stem Cell Clinic participated in a new clinical research study to investigate a stem cell product CTX0E03 DP, in order to improve function in people with chronic disability from ischemic stroke. Moreover, increasing prevalence of cancer is also expected to aid in growth of the market in North America. For instance, according to National Cancer Institute, in 2016, around 1,685,210 new cases of cancer were diagnosed in the U.S. alone.

Among cell sources, the adult stem cells segment accounted for the largest market share in the global stem cell therapy market in 2018. This is attributed to significant developments related to adult stem cells. For instance, in October 2016, Pall Corporation and RoosterBio Inc., an adult stem cell technology company, announced a co-development and marketing partnership. Under this partnership, the companies offered solutions for expansion of large-scale bioreactors of human mesenchymal stem/stromal cells (hMSCs) to accelerate product development and commercialization of stem cell based therapies in the market.

Key players in the market are focused on launching new products to expand their product portfolio. For instance, in January 2019, STEMCELL Technologies launched mTeSR Plus, a feeder-free human pluripotent stem cell (hPSC) maintenance medium for avoiding conditions associated with DNA damage, genomic instability, and growth arrest in hPSCs. Similarly, in February 2018, the Institute of Integrative Biology entered into a collaboration with Anika Therapeutics, Inc., to develop an injectable mesenchymal stem cell (MSC) therapy for the treatment of osteoarthritis in patients. In 2016, Axiogenesis AG and Metrion Biosciences Ltd. entered into a collaboration to validate, optimize, and commercialize induced pluripotent stem cell-derived cells and tissues, to speed up research in drug discovery

To know the latest trends and insights prevalent in the Stem Cell Therapy Market Press Release, click the link below: https://www.coherentmarketinsights.com/press-release/stem-cell-therapy-market-to-surpass-us-336-billion-by-2026-1714

Key Takeaways

Key players operating in the global stem cell therapy market include Magellan, Medipost Co., Ltd, Osiris Therapeutics, Inc., Kolon TissueGene, Inc., JCR Pharmaceuticals Co., Ltd., Anterogen Co. Ltd., Pharmicell Co., Inc., and Stemedica Cell Technologies, Inc.

About Us:

Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients achieve transformational growth by helping them make critical business decisions. We are headquartered in India, having office at global financial capital in the U.S. and sales consultants in United Kingdom and Japan. Our client base includes players from across various business verticals in over 150 countries worldwide. We pride ourselves in catering to clients across the length and width of the horizon, from Fortune 500 enlisted companies, to not-for-profit organization, and startups looking to establish a foothold in the market. We excel in offering unmatched actionable market intelligence across various industry verticals, including chemicals and materials, healthcare, and food & beverages, consumer goods, packaging, semiconductors, software and services, Telecom, and Automotive. We offer syndicated market intelligence reports, customized research solutions, and consulting services.

To know more about us, please visit our website http://www.coherentmarketinsights.com

Contact:

Coherent Market Insights 1001 4th Ave, #3200 Seattle, WA 98154, U.S. Email:sales@coherentmarketinsights.com United States of America: +1-206-701-6702 United Kingdom: +44-020-8133-4027 Japan: +050-5539-1737 India: +91-848-285-0837

This content has been distributed via CDN Newswire press release distribution service. For press release enquires please mail us at contact@cdnnewswire.com.

See original here:
Stem Cell Therapy Market to Surpass US$ 40.3 Billion by 2027, Owing to Increasing Incidence of Spina - PharmiWeb.com

Shifting the focus in healthcare to primordial prevention – ETHealthworld.com

By Dr. Srivats Bharadwaj, Chairman & CEO, Vatsalya Dental, Bengaluru

We are living through what is perhaps the worst collective nightmare in recent times, one with no end in sight. Covid-19 has spread with alarming speed and intensity infecting millions, killing hundreds of thousands, and leaving many in recovery with debilitating side effects. The pandemic has had unprecedented socio-economic implications.

Yet, the most glaring observation of the pandemic is also the most ironical - any knowledgeable medical professional will tell you that they saw this coming for a while now. Global spending on health has risen drastically in recent years to US$ 7.8 trillion in 2017, or about 10% of GDP mostly on intervention led research and care.

Covid-19 has focused the spotlight on the sheer unpreparedness and inability of our healthcare systems to cope with threats of this magnitude. It has also driven home the lacunae in infection control measures at the individual and institutional levels, forcing people and households to embrace a highly clinical approach to infection control. There is a dire need to recast our individual lifestyles, healthcare policies, research and infrastructure to shift gears to primordial prevention and preventive research.

What is primordial prevention?

Primordial prevention addresses the root cause of risk factors to prevent the onset and growth of illnesses and diseases. It refers to measures taken to stem the development of these ailments, rather than reacting to control their effects.

These preventive measures are rooted in the intersection of environmental, economic, social, cultural and behavioral conditions and practices. In fact, the traditional Indian socio-cultural ethos has always incorporated primordial preventive healthcare as a way of life. If you grew up in India in the last century, you would have likely followed some of the following practices at home:

With advancement in sciences and lifestyle, however, a lot of these practices changed as we blindly aped the western way of life. Despite tremendous appreciable progress in modern medicine, the focus in the last few decades has shifted drastically from preventive medical support to reactive, intervention-led care.

In todays world of instant gratification, we have begun to glorify acute care measures as the results are obvious and immediate, and this has become the norm. But the focus on intervention only provides short-lived results and the healthcare system falls apart in the face of a true challenge such has the pandemic we are now living through.

The case for investing in primordial prevention

Primordial prevention is an intangible entity and therefore, not given its due value as it is tough to quantify the benefits and outcomes of preventive measures. Comparison against other parameters also becomes difficult with no immediate, visible results.

Added to this is the natural tendency of the human mind and our conditioning (and modern media focus) to associate and drive cause-benefit correlations only between recent events and occurrences. This is driven by our strong recall of immediate events and poor long-term memory. Consider this: Until Coronavirus surfaced, we had mostly forgotten the devastating effects of the 1918 Spanish Flu, one of the worst epidemics that we could have learnt so much from.

It is also human nature to overreact to immediate problems staring us in the face and under-react to long-term threats that build up slowly over time. However, if one needed numbers to substantiate the import of investing in primordial preventive healthcare, take this. Preliminary estimates in May 2020 by the Asian Development Bank suggests a USD 5.8 8.8 trillion loss to the global economy due to Covid19. And actuals could be much worse depending on how long the pandemic lasts. Not to mention the loss of over 610,000 lives at the time of drafting this article.

Covid-19 will not be the last pandemic we see in this century. Healthcare globally needs a thorough rehaul and we must shift gears from reactive panic to preventive preparation. Heres how:

The cost and effort of prevention is extremely high can we afford it? But then, the present nightmare also begs us to ask, can we afford to not do it? The medical fraternity needs to stop focusing on treating heart attacks and strokes, and instead, focus on preventing them. At the individual and social level, we need to re-establish some of the validated lifestyle practices from yore that aid infection control. The time to shift focus to primordial preventive healthcare is NOW. And the way to do it is to take a step back in time and lifestyle practices, in order to move forward.

DISCLAIMER: The views expressed are solely of the author and ETHealthworld.com does not necessarily subscribe to it. ETHealthworld.com shall not be responsible for any damage caused to any person/organisation directly or indirectly.

See the rest here:
Shifting the focus in healthcare to primordial prevention - ETHealthworld.com

Embryonic Stem-Cell Research: The Promise and the Reality …

by Charles Whitaker Forerunner, "Prophecy Watch," July 2006 2006-07-01

"Know that the Lord, He is God; It is He who has made us, and not we ourselves." Psalm 100:3

Embryonic stem-cell research is both scientifically feasible and morally permissibleat least according to the majority of the electorate in the State of California. In the November 2004 elections, an overwhelming majority of those voters approved an initiative that funds embryonic stem-cell research through $3 billion worth of bonds. Emotion rather than reason probably generated most of the "aye" votes, many voters responding to the biotech industry's marketing ploy of airing testimonials from desperately sick or injured celebrities. "Don't deny us the only hope we have," they pled. "A vote against embryonic stem-cell research is a vote against life."

California's electorate asideand apparently many in both Houses of Congress, where stem-cell research bills are now being debated, as wellis the harvesting of embryonic stems cells in fact moral? Is there any substantive scientific evidence that embryonic stem-cell research can make good on its promises to cure? Who loses from this research? Who gains?

In this two-part article, we will review embryonic stem-cell research: its nature and goals, its scientific challenges, its moral issues, and its alternatives. What is it all about?

Let us start by getting the terms straight.

Embryology 101

(Underlined words are defined in the glossary at the end.)

There are two types of human reproduction: sexual and asexual. In sexual reproduction, the male gamete (or sperm cell) unites with the female gamete (or egg cell) to produce a zygote. This union is called fertilization. Half the chromosomes of the zygote come from the sperm cell, half from the egg cell.

Sexual reproduction comes in two varieties. The first, and more common, is fertilization through coition. This is in utero fertilization, where the zygote comes into being in the uterus. The second kind is in vitro fertilization (IVF), where the sperm unites with an egg in a laboratory Petri dish. From that point, the zygote (and later, the embryo) can develop in culture.

Asexual reproduction is commonly called cloning. Procedurally, the nucleus of an egg cell is removed in the laboratory. Then, the nucleus from another type of cell, any body cell, is "inserted" into that egg cell. Stimulating this egg cell with an electrical charge creates a viable zygote.

While not usually part of the syllabus of Embryology 101, it is important to understand two things about embryos.

1. First, every human zygote, no matter how it is produced, is a human being who is in his first stage of development. Every zygote is an individual. Unless death intervenes, the zygote will become an embryo, then a fetus, then an infant, then an adolescent, and eventually an adult.

2. Second, the absence of a sperm does not render an embryo created through cloning anything less than a full-fledged embryo. A cloned embryo is an embryo in every sense of the term. One writer mentions that even a stem-cell researcher as prominent as John Gearhard of Johns Hopkins University insists that the cloned organism starts out its existence as a zygote/embryo.1

Upon its creation, the zygote has two tasks immediately ahead of it. In the case of natural conception, it must implant itself into the wall of the womb. If it does not accomplish this implantation soon, it will perish for lack of nourishment. All human life, at whatever stage, must have sustenance and a proper environment to continue living.2

Embryology Development

The zygote's other task is to growto split into more cells. It starts this process almost immediately, and in the case of in utero fertilization, long before womb-attachment. Growing, the zygote becomes an embryo and later a fetus. Importantly, initial growth does not simply mean adding more cells; it does not merely imply "getting bigger." At this point, adding size, as a boy does when he "bulks up" by exercising his muscles, is not the aim in a person's development. Instead, from the single-cell zygote must spring each of the 210 basic cell types in the human body. Examples of such cell types include brain cells, bone cells, red blood cells. These are called adult cells.

Adult cells by definition perform highly specialized tasks. Red blood cells provide a good example of this specialization. Their task is to supply oxygen to other cells. They are able to carry out that task because they have iron in them. The iron oxidizes; it rusts. (That is why "red" blood cells appear red.) The oxidization process means that oxygen becomes attached to the iron. It is in fact the rusted iron, carried by these red blood cells, which provides oxygen to other cells.

The zygote's task, then, is not just to add numbers of cells, but to produce 210 different types of adult cells. The process by which a zygote does this is called cellular differentiation. Here is where embryonic stem cells enter the picture. When a zygote begins to split into other cells, it does not form specialized, adult cells. Rather, it forms stem cells. These stem cells facilitate cellular differentiation. Stem in this usage means "source" or "origin," as in the sentence, "Adultery stems from lustful thoughts." Thus, specialized (adult) cells stem from stem cells.

Cellular differentiation works this way: When a stem cell divides, it forms two cells.

One is a look-alike; it replaces the original stem cell.

The other cell is truly remarkable; it has the ability to split into something new. That something new is a differentiated stem cell, and it is quite different from the stem cell that produced it. This new stem cell is a more specialized cell, but it is not yet an adult cell.

A Stepping-Stone Process

Think of this new, different stem cell as one "stepping stone" toward the final product, an adult cell. Between original zygote and final adult cell, several stepping-stones will be needed. Each stone brings you closer to that adult cell. With each successive splitting of a stem cell, a more specialized cell comes into being, until, after a number of "generations," the adult cell appears. That cell may be, say, a red blood cellhighly specialized in its function. It could be a white blood cell, a brain cell, a bone cellany of 210 distinct types of adult cells.

What might be the basic difference between stem cells and adult cells? It is probably the type of cells they are capable of producing.

Adult cells can produce only after their kind. A white blood cell cannot breed a brain cell, but only another white blood cell.

However, the zygote and stem cells are able to produce cells quite different from themselves. The zygote is called totipotentable to generate all other cells. The earliest stem cells, those descending directly from the zygote, are also characterized by totipotency; they, too, can ultimately (that is, through several "generations" of splits) produce all other types of cellsbrain cells, bone cells, etc.

Importantly, this differentiation is not random but is tightly organized. Something signals a particular stem cell to act as the ultimate progenitor of a brain cell. That something also signals another stem cell to produce, after several generations, a liver cell. One expert summarizes the challenge this way:

Embryonic development is one of the most fascinating of all biological processes. A newly fertilized egg faces the daunting challenge of not only generating all of the tissues of the mature animal but organizing them into a functionally integrated whole. . . . If a developing embryo is not to end up a mass of disorganized tissues, it must do more than generate adult cell types. Embryos must orchestrate and choreograph an elaborate stage production that gives rise to a functional organism. They must direct intricate cell movements that bring together populations of cells only to separate them again, mold and shape organs through the birth of some cells and the death of others, and build ever more elaborate interacting systems while destroying others that serve only transient, embryonic functions. Throughout the ceaseless building, moving, and remodeling of embryonic development, new cells with unique characteristics are constantly being generated and integrated into the overall structure of the developing embryo. Science has only the most rudimentary understanding of the nature of the blueprint that orders embryonic development.3

Although not understood by man, this "blueprint that orders" is vitally important in the development of the individual. Stem cells that take ordersfollow the blueprintbuild healthy bodies. Stem cells that do not take orders result in a monster. Monster is the English translation of the Greek word teratoma, a type of tumor (benign or malignant) whose initial cells appear totipotent (or at least multipotent). They are like stem cells, keen to produce a wide variety of adult cell types (skin, bone, muscle, hair, teeth). However, the tissue they generate is "all massed together in a chaotic lump. . . . Unlike embryos, tumors generate adult cell types in a hopelessly undirected manner."4 The teratoma's initial stem-like cells lack a blueprint, or at least refuse to follow one. The result can be an often lethal, malignant monster.

Dissociated Embryonic Stem Cells

What is the nature of this ordering blueprint? Put differently: What generates the signals that tell a particular stem cell to differentiate into a red blood cell as distinct from a bone cell? How does a given stem cell know to generate a line of stem cells that will finally culminate in, say, an adult brain cell?

In this area, there are more questions than answers. Scientists know that there are three types of signals:

1. Molecular: Chemical substances are known to provide signals to embryonic stem cells.

2. Electrical: It is widely recognized that embryonic development takes place in an electrical field.

3. Mechanical: Embryonic stem cells seem to respond to structural tensions provided by cells in their proximity.

In the early 1990s, scientists learned that they could physically "extract" some stem cells from an embryo they had created through in vitro fertilization or through cloning. These separated (or "harvested") cells are called dissociated embryonic stem cells. In culture, these cells reproduce indefinitelyand fast! "One small flask of cells . . . will generate a quantity of stem cells roughly equivalent in weight to the entire human population of the earth in less than sixty days."5 However, these harvested stem cells simply reproduce; they do not differentiate into more and more specialized adult cell types. This is because they lack signals. Separated from the embryo, these dissociated cells find no blueprint to follow. They become a mass of unorganized (indeed, disorganized) cells, not unlike a teratoma.

This finding disheartened scientists until they discovered they could simulate (or replicate) those signals, or at least the chemical ones. Wow! What a blockbuster! Just provide the right signals, and there, in culture, is produced adult, disease-free cells of whatever type is needed to bring about a cure.

Let us say a scientist "signaled" these disassociated stem cells to differentiate, ultimately, into pancreatic cells, which are adult cells. Once produced in sufficient number, these adult pancreas cells could be implanted into a person with a bad pancreas, a diabetic. The effect, scientists promise, would be curative. The pancreas would eventually start producing insulin normally.

Such is the promise of embryonic stem-cell research. That is why the celebrities in California praised it so much. That is why a majority of voters added $3 billion to California's already burdensome indebtedness. The biotech firms love every minute (uh, dollar) of it!

In Search of a Better Blueprint

Bottom line, what is embryonic stem-cell research all about? Certainly, it is about determining which signal produces a pancreas cell, which produces a white blood cell, which one a bone cell, and so on. It is a search for effective signals to embryonic stem cells.

Far more fundamentally, however, it is a search for a blueprint. It is a search to find the organizing plan the zygote/embryo follows as it differentiates cells, configures them into systems, and integrates them into the single organism scientists call homo sapiens. In short, stem-cell research is the search for the pattern God uses to "fashion" us in the womb.6Psalm 139:13-16 makes it clear that God saw David's blueprint before his first stem cell split; the person David was the result of God's working "skillfully" according to that plan. David writes,

For You have formed my inward parts; You have covered me in my mother's womb. I will praise You, for I am fearfully and wonderfully made. . . . My frame was not hidden from You, When I was made in secret, And skillfully wrought in the lowest parts of the earth. Your eyes saw my substance, being yet unformed.

We can be sure that scientists, if they could figure out that blueprint, would want to make it "better." They would want to create their kind of person, a superman. Paying no attention at all to Psalm 100:3, they forget that man does not create man. God does.

Next month, we will look at the scientific challenges and moral issues that surround embryonic stem-cell research.

Glossary of Terms

Adult Cell A specialized cell, like a brain or heart cell. Unlike stem cells, an adult cell can produce cells only of its own type. Many biologists identify about 210 discreet types of adult cells.

Adult Stem Cells Stem cells present in the extra-uterine individual, retrievable by biopsy. Not to be confused with adult cells.

Cellular Differentiation The process by which stem cells generate cells quite different from themselves. The generated cells are different in that they are more specialized.

Cloning A fertilization process marked by the absence of a male gamete (sperm). The nucleus of an egg cell is removed in the laboratory. Then, the nucleus from any other body cell is "inserted" into that egg cell. Stimulating the egg cell with an electrical charge creates a zygote, which can develop in culture. The individual produced is said to be a clone of the donor who supplied the substituted nucleus.

Disassociated Embryonic Stem Cells Embryonic stem cells that are extracted from an embryo created through in vitro fertilization or through cloning. The cells so "harvested" from the embryo can be nurtured in culture, where they split indefinitely and quickly. The embryo that donates the stem cells dies.

Embryo An individual (human or animal) from the time the zygote first begins cellular differentiation. In the case of human, the organism is termed an embryo through the eighth week after fertilization.

Embryonic Stem Cells Stem cells that are the immediate descendants of the zygote. Responding to molecular, electrical, and mechanical stimuli (or signals), these cells produce more specialized stem cells, which in turn produce even more specialized stem cells. The ultimate product is an adult cell, such as a white or red blood cell.

Female Gamete Egg (ovum).

Fertilization The process by which the male gamete (sperm) unites with the female gamete (egg). The immediate result is a new individual in the zygote stage of development. Fertilization can be sexual, effected through coition or IVF, or asexual, effected through cloning.

Fetus In humans, an individual from the ninth week after fertilization until parturition (birth).

Implantation The process by which the zygote/embryo attaches itself to the womb for sustenance.

In utero Fertilization Sexual fertilization wherein the male gamete (sperm) unites with the female gamete (egg) in the uterus. This is coition, the traditional method of fertilization.

In vitro Fertilization Sexual fertilization wherein the male gamete (sperm) unites with the female gamete (egg) in a laboratory Petri dish. The embryo can then develop in culture. Acronym: IVF.

Male Gamete Sperm cell.

Multipotent Capable of differentiating into (that is, ultimately producing) a number of other types of cells, but not all types of cells, Multipotency is a characteristic of stem cells that are more than one generation away from original stem cells. Such cells are more specialized, and are less able to generate any type of cell. The more specialized a cell (that is, the more generations it is away from the original stem cells) the less multipotent it is. Also termed pluripotent.

Pre-Embryo An embryo before implantation in the womb. This term has no meaningful biological referent. "Pre-embryo" implies that the fertilized organism, before attachment to the womb, is not an embryo at all. By definition, however, the zygote became an embryo immediately after it began to split. In other words, an embryo is an embryo, regardless of its state of womb-attachment. Before attachment, an embryo is still an embryojust an un-implanted one. The term pre-embryo implies that a zygote/embryo is not a human organism until attachment and can therefore be destroyed. It is a term coined by politically-minded bio-technicians to give them "time" to kill, a window of time between fertilization and attachment. The term seeks to skirt the moral issue of murder.

Stem Cell A cell that becomes the source (hence, "stem") of other cells. Stem cells can produce more specialized cells, such as brain or bone cells. See totipotent and multipotent.

Teratoma A type of tumor resulting from multipotent (pluripotent) cells. Because the initial cells carry the characteristic of multipotency, they are similar to stem cells. However, the teratoma's cells follow no blueprint. They do not produce an organism with integrated systems, but a confused mass of tissue. In these tumors appear cell types quite different from that of the surrounding tissue (for instance, an ovarian teratoma may contain hair, teeth, and even sweat glands). Also referred to as teratomata.

Totipotent Able to differentiate into (that is, ultimately produce) all other types of cells. Totipotency is a characteristic of the zygote and of the stem cells that are its immediate progeny.

Zygote The highly specialized single cell resulting from fertilization.

Descriptive Bibliography

Campbell, Stuart, MD, Watch Me Grow! St. Martin's Press. Dr. Campbell trail-blazed the use of ultrasound. Watch Me Grow! presents a truly remarkable week-by-week window into human embryonic and fetal intrauterine development. These are not the blurry images of early ultrasound, but beautifully clear and crisp 3-D and 4-D images of younguns on their way to parturition. Watch Me Grow! is 112 pages of awe-inspiring magnificence, a remarkable use of technology to display God's glory.

Colson, Charles and Cameron, Nigel, eds., Human Dignity in the Biotech Century: A Christian Vision for Public Policy, InterVarsity Press. This collection of surveys by experts covers every facet of modern biotechnology: IVF, cloning, stem-cell research, genetic engineering. Eric Cohen, editor of the New Atlantis, reviews this book in the January 2005 number of First Things (http://www.firstthings.com/ftissues/ft0501/reviews/cohen.htm).

Condic, L. Maureen, "The Basic Facts about Stem Cells," First Things, January 2002, p. 30. This short article provides the "must know" facts about stem-cell research. This article is available at http://www.firstthings.com/ftissues/ft0201/articles/condic.html.

Condic, "Stem Cells and False Hopes," First Things, August/September 2002, p. 20. Ms. Condic, Assistant Professor of Neurobiology and Anatomy at the University of Utah, discusses the exploitation of desperately sick individuals by biotech firms. This article is available at http://www.firstthings.com/ftissues/ft0208/opinion/condic.html.

Saunders, Jr., William L., "Embryology: Inconvenient Facts," First Things, December 2004, p. 15. Saunders, Senior Fellow and Director of the Center for Human Life and Bioethics, presents authoritative arguments for the nature of zygote and embryo, and shows how modern bio-technicians hide meaning behind verbal sophistries. This article is available at http://www.firstthings.com/ftissues/ft0412/opinion/saunders.htm

National Catholic Bioethics Quarterly. This big journal (each issue is over 200 pages) is published by the National Catholic Bioethics Center in Boston. Because of the obvious Catholic focus, members of God's church will find many articles off base, yet this journal remains one of the best single sources of reasoned information on the subjects of bioethics and biotechnology. Some articles are quite technical. For more information, write the National Catholic Bioethics Quarterly, PO Box 3000, Denville, NJ 07834-9772 ($48/year).

Endnotes

1 Saunders, Jr., William L, "Embryology: Inconvenient Facts," First Things, December 2004, p. 15. 2 After the mid-1980s, bio-technicians spoke of a pre-embryo as an organism before womb-attachment. The implication is that the pre-embryo is non-human; the implanted embryo human. This false concept will be discussed more fully in Part Two. Suffice it to say that there is really no such thing as a pre-embryo. An embryo is an embryo. An unattached one is an embryo in every sense of the definition. It is just unattached. 3 Condic, Maureen, "The Basics about Stem Cells," First Things, January 2002, p 30. 4 Ibid. 5 Ibid. 6 See Psalm 119:73.

Original post:
Embryonic Stem-Cell Research: The Promise and the Reality ...